Abstract Glucose homeostasis requires the coordinated actions of various organs and is critically dependent on the proper functioning of the various cell types present in the pancreatic Langerhans islets. Here we report that chromatin architectural protein HMGN3 is highly expressed in all pancreatic endocrine islet cells, and that Hmgn3 −/− mice which have a mild diabetic phenotype, have reduced glucagon levels in their blood. To elucidate the mechanism leading to altered glucagon secretion of Hmgn3 −/− mice, we tested whether HMGN3 affect glucagon synthesis and secretion in αTC1‐9 cells, a glucagon secreting cell line that is used to study pancreatic α‐cell function. We find that in these cells deletion of either HMGN3 or other HMGN variants, does not significantly affect glucagon gene expression or glucagon secretion. Our studies demonstrate a link between HMGN3 and glucagon blood levels that is not directly dependent of the function of pancreatic α‐cells. J. Cell. Biochem. 109: 49–57, 2010. Published 2009 Wiley‐Liss, Inc.
Abstract-In general, it tends to become a complex and expensive structure in the controlling of flow rate. In this paper, a simple structure and compact flow rate servo system is shown. It is easy to carry by integrating needed element, that is, the solenoid valve, the isothermal pressure vessel, the pressure sensor and oneboard controller of on-off method, although, the external compressor is needed. The signal measured with the pressure sensor is sent to the controller, and the proper control signal is feedback to the switching transistor according to on-off timing of the solenoid valve. In this method, the small pressure fluctuation caused by switching action of solenoid valve can not be avoided, however, this pressure fluctuation enables to examine the actual output flow rate by on-line sampling the pressure and calculation using micro processor on controller. So we execute continuous flow rate controlby this compact system alone, and are able to change the output flow rate freely according to manual set up or external control signal. For the evaluation of this system, the blowing up device is adopted to confirm the accuracy of flow rate that is constantly controlled ball height apart from seat.
Abstract In nanoimprint lithography (NIL), a residual layer inherently exists under the NIL resist features and must be removed in later etching steps. The subsequent etching process, known as breakthrough etching, leads to variations in the device pattern sizes and disrupts process integration because of NIL resist pattern loss. It was reported previously that the residual layer thickness (RLT) should be less than half the feature height (FH) for subsequent high-precision etching. In this work, we develop a one-pass etching process using an atomic-scale cycle stepped etching technique that passes through the residual layer to the spin-on-glass and demonstrate that the process can maintain the pattern width, regardless of RLT variations within the 12–32 nm thickness range. Even in the case of a 32-nm-thick RLT corresponding to 76% of the feature height (0.76 FH), good electrical performances were obtained without electrical failures in the half-pitch 26 nm line-and-space W-damascene interconnect patterns.
To determine the effectiveness of baricitinib in patients with coronavirus disease 2019 (COVID-19), investigate whether baricitinib prevents the need for invasive mechanical ventilation and identify patient subgroups that would benefit from baricitinib.This observational matched-cohort study was conducted by the Japan COVID-19 Task Force, a nationwide multicenter consortium. Patients with COVID-19 aged ≥18 years were identified from 70 hospitals in Japan. Among patients with confirmed COVID-19 from February 2020 to September 2021, those receiving baricitinib were propensity-score matched with controls.Among 3309 patients, 144 propensity score-matched pairs were identified. Thirteen (9.0%) patients in the baricitinib group and 27 (18.8%) in the control group required invasive mechanical ventilation during the disease course (odds ratio, 0.43). Although the baricitinib group had more severe disease, there were no significant differences in the intensive care unit admission rates (odds ratio, 1.16) and mortality rates (odds ratio, 0.74) between groups. In subgroup analyses, baricitinib was associated with a significant reduction in the need for invasive mechanical ventilation in patients requiring oxygen support (odds ratio, 0.28), with rapid shadow spread on chest radiography (odds ratio, 0.11), or treated with remdesivir (odds ratio, 0.27), systemic corticosteroids (odds ratio, 0.31), or anticoagulants (odds ratio, 0.17).Baricitinib is effective at preventing the need for invasive mechanical ventilation in patients with COVID-19.
The predictive value of combined 123 iodine-labelled 15-( p-iodophenyl)-3 R,S-methyl pentadecanoic acid imaging ( 123 I-BMIPP) and early technetium-99m ( 99m Tc)-tetrofosmin imaging was compared with combined 123 I-BMIPP and delayed 99m Tc-tetrofosmin or 123 I-BMIPP and thallium-201 ( 201 Tl) imaging for functional outcome of stunned myocardium after acute myocardial infarction (AMI) in 37 patients with AMI. All patients underwent successful percutaneous coronary intervention with/without stenting within 24 h of symptoms. Resting 201 Tl, 99m Tc-tetrofosmin and 123 I-BMIPP imaging were performed within 10 days of hospital admission; 99m Tc-tetrofosmin imaging was also performed 6 months later. Segments were mismatched when the 123 I-BMIPP score was greater than the 99m Tc-tetrofosmin or 201 Tl scores, and were matched when all scores were the same. Left ventricular function was estimated using wall motion score. Sensitivity and regional wall motion were significantly better in mismatching 99m Tc-tetrofosmin-early/ 123 I-BMIPP segments than mismatching 201 Tl/ 123 I-BMIPP or 99m Tc-tetrofosmin-delayed/ 123 I-BMIPP segments. It is concluded that mismatching of 123 I-BMIPP and early 99m Tc-tetrofosmin uptake can predict improvement in wall motion of stunned myocardium better than the other two imaging combinations.